NCT00265343View on ClinicalTrials.gov

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)

PHASE3CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

January 31, 2008

Conditions
Schizophrenia
Interventions
DRUG

asenapine

5-10 mg sublingually twice daily for 26 weeks

DRUG

olanzapine

5-20 mg by mouth once daily for 26 weeks

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00265343 - 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777) | Biotech Hunter | Biotech Hunter